02
янв
MOTILIUM® tablets PATIENT INFORMATION MOTILIUM® tablets SCHEDULING STATUS Schedule 2. PROPRIETARY NAME (and dosage form) MOTILIUM ® tablets COMPOSITION Each tablet contains 10 mg domperidone. PHARMACOLOGICAL CLASSIFICATION A.5.7.2 Anti-emetics and anti-vertigo preparations.
PHARMACOLOGICAL ACTION Domperidone is a dopamine-receptor blocking agent. Its action on the dopamine-receptors in the chemo-emetic trigger zone produces an anti-emetic effect. Domperidone does not cross the blood-brain barrier to any appreciable degree and so exerts relatively little effect on cerebral dopaminergic receptors. Domperidone has been shown to increase the duration of antral and duodenal contractions to increase gastric emptying.
Domperidone does not alter gastric secretions and has no effect on intracranial pressure or on the cardiovascular system. Domperidone is rapidly absorbed, with peak plasma concentrations at approximately 1 hour after oral administration. The absolute bio-availability of oral domperidone is low (approximately 15%) due to first-pass hepatic and intestinal metabolism. Domperidone is 91 to 93% bound to plasma proteins.
Motilium (also called Domperidone (sp.?) is likewise used for (as the name suggests) gastroparesis, meaning delayed digestion. It works like Reglan, w/o many of the ugly side effects. One thing -- it can cause lactation in women.
The plasma half-life after a single oral dose is 7 to 9 hours in healthy subjects but is prolonged in patients with severe renal insufficiency. Domperidone undergoes rapid and extensive hepatic metabolism by hydroxylation and N-dealkylation. In vitro metabolism experiments with diagnostic inhibitors revealed that CYP3A4 is a major form of cytochrome P-450 involved in the N-dealkylation of domperidone, whereas CYP3A4, CYP1A2 and CYP2E1 are involved in domperidone aromatic hydroxylation.
Urinary and faecal excretion amount to 31% and 66% of the oral dose, respectively. The proportion of drug excreted unchanged is small (approximately 1% of urinary and 10% of faecal excretion).
INDICATIONS MOTILIUM is indicated for: - Delayed gastric emptying of functional origin with gastro-oesophageal reflux and/or dyspepsia. - Control of nausea and vomiting of central or local origin. - As an anti-emetic in patients receiving cytostatic and radiation therapy. - Facilitates radiological examination of the upper gastro-intestinal tract.
CONTRA-INDICATIONS MOTILIUM is contra-indicated in patients with known hypersensitivity to domperidone. MOTILIUM should not be used whenever stimulation of gastric motility is to be avoided or could be harmful, eg. In the presence of gastro-intestinal haemorrhage, obstruction or perforation. 
MOTILIUM is also contra-indicated in patients with a prolactin-releasing pituitary tumour (prolactinoma). The safety of use during pregnancy and lactation has not been established.
DOSAGE AND DIRECTIONS FOR USE Acute conditions (mainly nausea, vomiting, hiccup) Adults: Two tablets (20 mg) 3 to 4 times per day, 15 to 30 minutes before meals and, if necessary, before retiring. Children 5 to 12 years old: One tablet (10 mg) 3 to 4 times per day, 15 to 30 minutes before meals and, if necessary, before retiring. Chronic conditions (mainly dyspepsia) Adults: One tablet (10 mg) taken 3 times per day, 15 to 30 minutes before meals and, if necessary, before retiring. The dosage may be doubled.
Children 5 to 12 years old: ½ tablet (5 mg) 3 to 4 times per day, 15 to 30 minutes before meals and if necessary, before retiring. This formulation is not suited for children under the age of 5 years, but for this group of patients the suspension is available. MOTILIUM should be used with caution in patients with renal impairment or in those at risk of fluid retention. In patients with severe renal insufficiency ( serum creatinine more than 6 mg/100 mL, ie. More than 0,6 mmol/L) the elimination half-life of domperidone was increased from 7,4 to 20,8 hours. The dosing frequency should be reduced to once or twice daily, depending on the severity of impairment, and the dose may need to be reduced. Patients on prolonged therapy should be reviewed regularly.
Popular Posts
MOTILIUM® tablets PATIENT INFORMATION MOTILIUM® tablets SCHEDULING STATUS Schedule 2. PROPRIETARY NAME (and dosage form) MOTILIUM ® tablets COMPOSITION Each tablet contains 10 mg domperidone. PHARMACOLOGICAL CLASSIFICATION A.5.7.2 Anti-emetics and anti-vertigo preparations.
PHARMACOLOGICAL ACTION Domperidone is a dopamine-receptor blocking agent. Its action on the dopamine-receptors in the chemo-emetic trigger zone produces an anti-emetic effect. Domperidone does not cross the blood-brain barrier to any appreciable degree and so exerts relatively little effect on cerebral dopaminergic receptors. Domperidone has been shown to increase the duration of antral and duodenal contractions to increase gastric emptying.
Domperidone does not alter gastric secretions and has no effect on intracranial pressure or on the cardiovascular system. Domperidone is rapidly absorbed, with peak plasma concentrations at approximately 1 hour after oral administration. The absolute bio-availability of oral domperidone is low (approximately 15%) due to first-pass hepatic and intestinal metabolism. Domperidone is 91 to 93% bound to plasma proteins.
Motilium (also called Domperidone (sp.?) is likewise used for (as the name suggests) gastroparesis, meaning delayed digestion. It works like Reglan, w/o many of the ugly side effects. One thing -- it can cause lactation in women.
The plasma half-life after a single oral dose is 7 to 9 hours in healthy subjects but is prolonged in patients with severe renal insufficiency. Domperidone undergoes rapid and extensive hepatic metabolism by hydroxylation and N-dealkylation. In vitro metabolism experiments with diagnostic inhibitors revealed that CYP3A4 is a major form of cytochrome P-450 involved in the N-dealkylation of domperidone, whereas CYP3A4, CYP1A2 and CYP2E1 are involved in domperidone aromatic hydroxylation.
Urinary and faecal excretion amount to 31% and 66% of the oral dose, respectively. The proportion of drug excreted unchanged is small (approximately 1% of urinary and 10% of faecal excretion).
INDICATIONS MOTILIUM is indicated for: - Delayed gastric emptying of functional origin with gastro-oesophageal reflux and/or dyspepsia. - Control of nausea and vomiting of central or local origin. - As an anti-emetic in patients receiving cytostatic and radiation therapy. - Facilitates radiological examination of the upper gastro-intestinal tract.
CONTRA-INDICATIONS MOTILIUM is contra-indicated in patients with known hypersensitivity to domperidone. MOTILIUM should not be used whenever stimulation of gastric motility is to be avoided or could be harmful, eg. In the presence of gastro-intestinal haemorrhage, obstruction or perforation.
MOTILIUM is also contra-indicated in patients with a prolactin-releasing pituitary tumour (prolactinoma). The safety of use during pregnancy and lactation has not been established.DOSAGE AND DIRECTIONS FOR USE Acute conditions (mainly nausea, vomiting, hiccup) Adults: Two tablets (20 mg) 3 to 4 times per day, 15 to 30 minutes before meals and, if necessary, before retiring. Children 5 to 12 years old: One tablet (10 mg) 3 to 4 times per day, 15 to 30 minutes before meals and, if necessary, before retiring. Chronic conditions (mainly dyspepsia) Adults: One tablet (10 mg) taken 3 times per day, 15 to 30 minutes before meals and, if necessary, before retiring. The dosage may be doubled.
Children 5 to 12 years old: ½ tablet (5 mg) 3 to 4 times per day, 15 to 30 minutes before meals and if necessary, before retiring. This formulation is not suited for children under the age of 5 years, but for this group of patients the suspension is available. MOTILIUM should be used with caution in patients with renal impairment or in those at risk of fluid retention. In patients with severe renal insufficiency ( serum creatinine more than 6 mg/100 mL, ie. More than 0,6 mmol/L) the elimination half-life of domperidone was increased from 7,4 to 20,8 hours. The dosing frequency should be reduced to once or twice daily, depending on the severity of impairment, and the dose may need to be reduced. Patients on prolonged therapy should be reviewed regularly.
...'>Motilium Skachatj Instrukciyu(02.01.2019)MOTILIUM® tablets PATIENT INFORMATION MOTILIUM® tablets SCHEDULING STATUS Schedule 2. PROPRIETARY NAME (and dosage form) MOTILIUM ® tablets COMPOSITION Each tablet contains 10 mg domperidone. PHARMACOLOGICAL CLASSIFICATION A.5.7.2 Anti-emetics and anti-vertigo preparations.
PHARMACOLOGICAL ACTION Domperidone is a dopamine-receptor blocking agent. Its action on the dopamine-receptors in the chemo-emetic trigger zone produces an anti-emetic effect. Domperidone does not cross the blood-brain barrier to any appreciable degree and so exerts relatively little effect on cerebral dopaminergic receptors. Domperidone has been shown to increase the duration of antral and duodenal contractions to increase gastric emptying.
Domperidone does not alter gastric secretions and has no effect on intracranial pressure or on the cardiovascular system. Domperidone is rapidly absorbed, with peak plasma concentrations at approximately 1 hour after oral administration. The absolute bio-availability of oral domperidone is low (approximately 15%) due to first-pass hepatic and intestinal metabolism. Domperidone is 91 to 93% bound to plasma proteins.
Motilium (also called Domperidone (sp.?) is likewise used for (as the name suggests) gastroparesis, meaning delayed digestion. It works like Reglan, w/o many of the ugly side effects. One thing -- it can cause lactation in women.
The plasma half-life after a single oral dose is 7 to 9 hours in healthy subjects but is prolonged in patients with severe renal insufficiency. Domperidone undergoes rapid and extensive hepatic metabolism by hydroxylation and N-dealkylation. In vitro metabolism experiments with diagnostic inhibitors revealed that CYP3A4 is a major form of cytochrome P-450 involved in the N-dealkylation of domperidone, whereas CYP3A4, CYP1A2 and CYP2E1 are involved in domperidone aromatic hydroxylation.
Urinary and faecal excretion amount to 31% and 66% of the oral dose, respectively. The proportion of drug excreted unchanged is small (approximately 1% of urinary and 10% of faecal excretion).
INDICATIONS MOTILIUM is indicated for: - Delayed gastric emptying of functional origin with gastro-oesophageal reflux and/or dyspepsia. - Control of nausea and vomiting of central or local origin. - As an anti-emetic in patients receiving cytostatic and radiation therapy. - Facilitates radiological examination of the upper gastro-intestinal tract.
CONTRA-INDICATIONS MOTILIUM is contra-indicated in patients with known hypersensitivity to domperidone. MOTILIUM should not be used whenever stimulation of gastric motility is to be avoided or could be harmful, eg. In the presence of gastro-intestinal haemorrhage, obstruction or perforation.
MOTILIUM is also contra-indicated in patients with a prolactin-releasing pituitary tumour (prolactinoma). The safety of use during pregnancy and lactation has not been established.DOSAGE AND DIRECTIONS FOR USE Acute conditions (mainly nausea, vomiting, hiccup) Adults: Two tablets (20 mg) 3 to 4 times per day, 15 to 30 minutes before meals and, if necessary, before retiring. Children 5 to 12 years old: One tablet (10 mg) 3 to 4 times per day, 15 to 30 minutes before meals and, if necessary, before retiring. Chronic conditions (mainly dyspepsia) Adults: One tablet (10 mg) taken 3 times per day, 15 to 30 minutes before meals and, if necessary, before retiring. The dosage may be doubled.
Children 5 to 12 years old: ½ tablet (5 mg) 3 to 4 times per day, 15 to 30 minutes before meals and if necessary, before retiring. This formulation is not suited for children under the age of 5 years, but for this group of patients the suspension is available. MOTILIUM should be used with caution in patients with renal impairment or in those at risk of fluid retention. In patients with severe renal insufficiency ( serum creatinine more than 6 mg/100 mL, ie. More than 0,6 mmol/L) the elimination half-life of domperidone was increased from 7,4 to 20,8 hours. The dosing frequency should be reduced to once or twice daily, depending on the severity of impairment, and the dose may need to be reduced. Patients on prolonged therapy should be reviewed regularly.
...'>Motilium Skachatj Instrukciyu(02.01.2019)